Genovis AB (publ.) (GENO.ST)
SEK 24.35
(2.31%)
SEK 24.35
(2.31%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 61.5 Million SEK | 449.55% |
| 2022 | 11.19 Million SEK | -54.83% |
| 2021 | 24.77 Million SEK | 284.39% |
| 2020 | 6.44 Million SEK | -32.51% |
| 2019 | 9.55 Million SEK | 658.45% |
| 2018 | -1.71 Million SEK | 78.48% |
| 2017 | -7.94 Million SEK | 47.12% |
| 2016 | -15.03 Million SEK | 24.49% |
| 2015 | -19.9 Million SEK | 9.72% |
| 2014 | -22.04 Million SEK | -39.09% |
| 2013 | -15.85 Million SEK | 20.4% |
| 2012 | -19.91 Million SEK | -46.35% |
| 2011 | -13.6 Million SEK | -20.52% |
| 2010 | -11.29 Million SEK | 35.69% |
| 2009 | -17.55 Million SEK | 35.33% |
| 2008 | -27.14 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.79 Million SEK | -85.95% |
| 2024 Q1 | 12.74 Million SEK | 3119.43% |
| 2023 Q1 | 43.56 Million SEK | 680.21% |
| 2023 Q2 | 15.21 Million SEK | -65.07% |
| 2023 Q3 | 3.13 Million SEK | -79.38% |
| 2023 FY | 61.5 Million SEK | 449.55% |
| 2023 Q4 | -422 Thousand SEK | -113.45% |
| 2022 Q2 | 672 Thousand SEK | -94.54% |
| 2022 FY | 11.19 Million SEK | -54.83% |
| 2022 Q3 | 5.7 Million SEK | 749.4% |
| 2022 Q4 | -7.5 Million SEK | -231.54% |
| 2022 Q1 | 12.31 Million SEK | -44.54% |
| 2021 Q3 | 854 Thousand SEK | -18.36% |
| 2021 Q4 | 22.2 Million SEK | 2500.4% |
| 2021 FY | 24.77 Million SEK | 284.39% |
| 2021 Q1 | 740 Thousand SEK | -91.47% |
| 2021 Q2 | 1.04 Million SEK | 41.35% |
| 2020 Q3 | 1.3 Million SEK | 185.49% |
| 2020 Q4 | 8.67 Million SEK | 566.04% |
| 2020 Q1 | -2 Million SEK | -208.89% |
| 2020 FY | 6.44 Million SEK | -32.51% |
| 2020 Q2 | -1.52 Million SEK | 24.08% |
| 2019 FY | 9.55 Million SEK | 658.45% |
| 2019 Q4 | -649.42 Thousand SEK | -108.92% |
| 2019 Q1 | 1.56 Million SEK | 19.42% |
| 2019 Q2 | 1.35 Million SEK | -13.49% |
| 2019 Q3 | 7.28 Million SEK | 438.29% |
| 2018 Q2 | -1.92 Million SEK | -30.75% |
| 2018 FY | -1.71 Million SEK | 78.48% |
| 2018 Q4 | 1.3 Million SEK | 252.05% |
| 2018 Q3 | 372 Thousand SEK | 119.35% |
| 2018 Q1 | -1.47 Million SEK | -18.98% |
| 2017 FY | -7.94 Million SEK | 47.12% |
| 2017 Q4 | -1.23 Million SEK | 23.21% |
| 2017 Q2 | -2.03 Million SEK | 29.02% |
| 2017 Q1 | -2.87 Million SEK | -18.11% |
| 2017 Q3 | -1.6 Million SEK | 21.01% |
| 2016 FY | -15.03 Million SEK | 24.49% |
| 2016 Q4 | -2.43 Million SEK | -127.1% |
| 2016 Q2 | -8.14 Million SEK | -140.42% |
| 2016 Q1 | -3.38 Million SEK | -10.63% |
| 2016 Q3 | -1.07 Million SEK | 86.86% |
| 2015 Q3 | -6.46 Million SEK | -20.36% |
| 2015 Q4 | -3.06 Million SEK | 52.66% |
| 2015 FY | -19.9 Million SEK | 9.72% |
| 2015 Q1 | -5 Million SEK | 36.35% |
| 2015 Q2 | -5.37 Million SEK | -7.37% |
| 2014 Q3 | -5.54 Million SEK | -15.45% |
| 2014 FY | -22.04 Million SEK | -39.09% |
| 2014 Q1 | -3.83 Million SEK | 27.77% |
| 2014 Q2 | -4.8 Million SEK | -25.14% |
| 2014 Q4 | -7.86 Million SEK | -41.78% |
| 2013 Q1 | -3.94 Million SEK | 52.64% |
| 2013 FY | -15.85 Million SEK | 20.4% |
| 2013 Q4 | -5.31 Million SEK | -93.92% |
| 2013 Q3 | -2.74 Million SEK | 28.87% |
| 2013 Q2 | -3.85 Million SEK | 2.38% |
| 2012 FY | -19.91 Million SEK | -46.35% |
| 2012 Q2 | -4.39 Million SEK | -10.63% |
| 2012 Q3 | -3.22 Million SEK | 26.66% |
| 2012 Q4 | -8.33 Million SEK | -158.65% |
| 2012 Q1 | -3.97 Million SEK | -3.47% |
| 2011 Q1 | -3.45 Million SEK | -4.77% |
| 2011 Q2 | -3.3 Million SEK | 4.37% |
| 2011 Q3 | -3 Million SEK | 9.07% |
| 2011 Q4 | -3.83 Million SEK | -27.6% |
| 2011 FY | -13.6 Million SEK | -20.52% |
| 2010 Q2 | -3.69 Million SEK | -55.73% |
| 2010 FY | -11.29 Million SEK | 35.69% |
| 2010 Q1 | -2.37 Million SEK | 70.96% |
| 2010 Q4 | -3.3 Million SEK | -15.28% |
| 2010 Q3 | -2.86 Million SEK | 22.5% |
| 2009 Q3 | -3.05 Million SEK | -6.12% |
| 2009 Q1 | -3.46 Million SEK | 0.0% |
| 2009 FY | -17.55 Million SEK | 35.33% |
| 2009 Q4 | -8.16 Million SEK | -167.81% |
| 2009 Q2 | -2.87 Million SEK | 17.08% |
| 2008 FY | -27.14 Million SEK | 0.0% |
| 2008 Q1 | -3.56 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Active Biotech AB (publ) | -45.8 Million SEK | 234.279% |
| Biovica International AB (publ) | -124.82 Million SEK | 149.27% |
| Cantargia AB (publ) | -280.02 Million SEK | 121.962% |
| CombiGene AB (publ) | -35.66 Million SEK | 272.436% |
| Cyxone AB (publ) | -22.98 Million SEK | 367.519% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 626.631% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 475.046% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 167.286% |
| Fluicell AB (publ) | -26.55 Million SEK | 331.604% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 149.972% |
| Mendus AB (publ) | -101.61 Million SEK | 160.52% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 265.898% |
| I-Tech AB | 20.2 Million SEK | -204.41% |
| Intervacc AB (publ) | -102.85 Million SEK | 159.795% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 607.091% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | -405.383% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 443.633% |
| OncoZenge AB (publ) | -15.9 Million SEK | 486.744% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 14141.096% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 115.843% |
| Lipum AB (publ) | -37.17 Million SEK | 265.42% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 124.74% |
| Ziccum AB (publ) | -21.41 Million SEK | 387.222% |
| BioArctic AB (publ) | 229.24 Million SEK | 73.173% |
| Camurus AB (publ) | 431.44 Million SEK | 85.745% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 134.582% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 208.235% |
| Aptahem AB (publ) | -11.11 Million SEK | 653.412% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 119.779% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 134.23% |
| Kancera AB (publ) | -64.88 Million SEK | 194.777% |
| Saniona AB (publ) | -95.81 Million SEK | 164.19% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 245.655% |
| AcouSort AB (publ) | -17.08 Million SEK | 459.881% |
| Xintela AB (publ) | -54.08 Million SEK | 213.714% |
| Abliva AB (publ) | -95.5 Million SEK | 164.392% |
| Karolinska Development AB (publ) | 5.38 Million SEK | -1041.849% |
| Amniotics AB (publ) | -30.87 Million SEK | 299.223% |
| 2cureX AB (publ) | -32.51 Million SEK | 289.126% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 579.42% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 113.192% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 107.394% |
| Biosergen AB | -27.03 Million SEK | 327.466% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 472.208% |
| Corline Biomedical AB | -1.8 Million SEK | 3499.668% |
| NextCell Pharma AB | -41.95 Million SEK | 246.569% |
| Nanologica AB (publ) | -75.15 Million SEK | 181.829% |
| LIDDS AB (publ) | -40.2 Million SEK | 252.962% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 118.813% |
| BioInvent International AB (publ) | -330.3 Million SEK | 118.619% |
| SynAct Pharma AB | -215.81 Million SEK | 128.497% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 239.601% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 359.089% |
| Alzinova AB (publ) | -16.48 Million SEK | 473.18% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 156.273% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 124.688% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 719.335% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 154.27% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 391.594% |
| Simris Alg AB (publ) | -37.3 Million SEK | 264.857% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 140.5% |